期刊
CANCER IMMUNOLOGY IMMUNOTHERAPY
卷 61, 期 4, 页码 497-509出版社
SPRINGER
DOI: 10.1007/s00262-011-1116-1
关键词
3D culture model; Breast cancer; Activated T cells; Bispecific antibody; Peripheral blood mononuclear cells; Myeloid-derived suppressor cells
资金
- National Cancer Institute [R01 CA 092344, R01 CA 140412, 5P39 CA 022453]
- Leukemia and Lymphoma Society [6066-06, 6092-09]
- Susan G. Komen Foundation [BCTR0707125]
- Michigan Cell Therapy Center for Excellence from the State of Michigan [1819]
- Barbara Ann Karmanos Cancer Institute
In this study, we investigated whether activated T cells (ATC) armed with bispecific antibodies (aATC) can inhibits tumor growth and MDSC development in a Th-1 cytokine-enriched (IL-2 and IFN-gamma) microenvironment. Cytotoxicity mediated by aATC was significantly higher (P < 0.001) against breast cancer cell lines in the presence of Th-1 cytokines as compared with control co-cultures. In the presence of aATC, CD33(+)/CD11b(+)/CD14(-)/HLA-DR- MDSC population was reduced significantly under both control (P < 0.03) and Th-1-enriched (P < 0.036) culture conditions. Cytokine analysis in the culture supernatants showed high levels of MDSC suppressive chemokines CXCL9 and CXCL10 in Th-1-enriched culture supernatants with highly significant increase (P < 0.001) in the presence of aATC. Interestingly, MDSC recovered from co-cultures without aATC showed potent ability to suppress activated T-cell-mediated cytotoxicity (P < 0.001), IFN-gamma production (P < 0.01) and T-cell proliferation (P < 0.05) compared to those recovered from aATC-containing co-cultures. These data suggest that aATC can mediate enhanced killing of tumor cells and may suppress MDSC and T-reg differentiation, and presence of Th-1 cytokines potentiates aATC-induced suppression of MDSC, suggesting that Th-1-enriching immunotherapy may be beneficial in cancer treatment.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据